1	N-glycosylation	_	NN	_	_	8	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	glucose	_	NN	_	_	4	NMOD	_	_
4	transporter-1	_	NN	_	_	2	PMOD	_	_
5	(	_	(	_	_	6	P	_	_
6	Glut-1	_	NN	_	_	4	PRN	_	_
7	)	_	)	_	_	6	P	_	_
8	is	_	VBZ	_	_	0	ROOT	_	_
9	associated	_	VBN	_	_	8	VC	_	_
10	with	_	IN	_	_	9	VMOD	_	_
11	increased	_	VBN	_	_	13	NMOD	_	_
12	transporter	_	NN	_	_	13	NMOD	_	_
13	affinity	_	NN	_	_	10	PMOD	_	_
14	for	_	IN	_	_	13	NMOD	_	_
15	glucose	_	NN	_	_	14	PMOD	_	_
16	in	_	IN	_	_	13	NMOD	_	_
17	human	_	JJ	_	_	19	NMOD	_	_
18	leukemic	_	JJ	_	_	19	NMOD	_	_
19	cells	_	NNS	_	_	16	PMOD	_	_
20	.	_	.	_	_	8	P	_	_
		
1	To	_	TO	_	_	20	VMOD	_	_
2	elucidate	_	VB	_	_	1	IM	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	role	_	NN	_	_	2	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	N-glycosylation	_	NN	_	_	5	PMOD	_	_
7	in	_	IN	_	_	4	NMOD	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	functional	_	JJ	_	_	10	NMOD	_	_
10	activity	_	NN	_	_	7	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	the	_	DT	_	_	15	NMOD	_	_
13	universal	_	JJ	_	_	15	NMOD	_	_
14	glucose	_	NN	_	_	15	NMOD	_	_
15	transporter	_	NN	_	_	11	PMOD	_	_
16	,	_	,	_	_	15	P	_	_
17	Glut-1	_	NN	_	_	15	APPO	_	_
18	,	_	,	_	_	20	P	_	_
19	we	_	PRP	_	_	20	VMOD	_	_
20	investigated	_	VBD	_	_	0	ROOT	_	_
21	effects	_	NNS	_	_	20	VMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	the	_	DT	_	_	27	NMOD	_	_
24	N-glycosylation	_	NN	_	_	27	NMOD	_	_
25	inhibitor	_	NN	_	_	27	NMOD	_	_
26	,	_	,	_	_	27	P	_	_
27	tunicamycin	_	NN	_	_	22	PMOD	_	_
28	,	_	,	_	_	27	P	_	_
29	on	_	IN	_	_	21	NMOD	_	_
30	glucose	_	NN	_	_	31	NMOD	_	_
31	transport	_	NN	_	_	29	PMOD	_	_
32	by	_	IN	_	_	31	NMOD	_	_
33	human	_	JJ	_	_	36	NMOD	_	_
34	leukemic	_	JJ	_	_	36	NMOD	_	_
35	cell	_	NN	_	_	36	NMOD	_	_
36	lines	_	NNS	_	_	32	PMOD	_	_
37	K562	_	NN	_	_	36	NMOD	_	_
38	,	_	,	_	_	36	P	_	_
39	U937	_	NN	_	_	36	APPO	_	_
40	and	_	CC	_	_	39	COORD	_	_
41	HL60	_	NN	_	_	40	CONJ	_	_
42	.	_	.	_	_	20	P	_	_
		
1	Treatment	_	NN	_	_	4	VMOD	_	_
2	with	_	IN	_	_	1	NMOD	_	_
3	tunicamycin	_	NN	_	_	2	PMOD	_	_
4	produced	_	VBD	_	_	0	ROOT	_	_
5	a	_	DT	_	_	8	NMOD	_	_
6	40-50	_	CD	_	_	8	NMOD	_	_
7	%	_	NN	_	_	6	AMOD	_	_
8	inhibition	_	NN	_	_	4	VMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	2-deoxyglucose	_	NN	_	_	11	NMOD	_	_
11	uptake	_	NN	_	_	9	PMOD	_	_
12	and	_	CC	_	_	4	COORD	_	_
13	this	_	DT	_	_	14	VMOD	_	_
14	was	_	VBD	_	_	12	CONJ	_	_
15	associated	_	VBN	_	_	14	VC	_	_
16	with	_	IN	_	_	15	VMOD	_	_
17	a	_	DT	_	_	19	NMOD	_	_
18	2-2.5-fold	_	RB	_	_	19	NMOD	_	_
19	decrease	_	NN	_	_	16	PMOD	_	_
20	in	_	IN	_	_	19	NMOD	_	_
21	transporter	_	NN	_	_	22	NMOD	_	_
22	affinity	_	NN	_	_	20	PMOD	_	_
23	for	_	IN	_	_	22	NMOD	_	_
24	glucose	_	NN	_	_	23	PMOD	_	_
25	(	_	(	_	_	26	P	_	_
26	Km	_	NN	_	_	22	PRN	_	_
27	)	_	)	_	_	26	P	_	_
28	without	_	IN	_	_	19	NMOD	_	_
29	a	_	DT	_	_	30	NMOD	_	_
30	change	_	NN	_	_	28	PMOD	_	_
31	in	_	IN	_	_	30	NMOD	_	_
32	Vmax	_	NN	_	_	31	PMOD	_	_
33	.	_	.	_	_	4	P	_	_
		
1	Leukemic	_	JJ	_	_	7	NMOD	_	_
2	K562	_	NN	_	_	7	NMOD	_	_
3	,	_	,	_	_	7	P	_	_
4	U937	_	NN	_	_	7	NMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	HL60	_	NN	_	_	5	CONJ	_	_
7	cells	_	NNS	_	_	8	VMOD	_	_
8	expressed	_	VBD	_	_	0	ROOT	_	_
9	Glut-1	_	NN	_	_	11	NMOD	_	_
10	transporter	_	NN	_	_	11	NMOD	_	_
11	protein	_	NN	_	_	8	VMOD	_	_
12	.	_	.	_	_	8	P	_	_
		
1	With	_	IN	_	_	5	VMOD	_	_
2	K562	_	NN	_	_	3	NMOD	_	_
3	cells	_	NNS	_	_	1	PMOD	_	_
4	Glut-1	_	NN	_	_	5	VMOD	_	_
5	appeared	_	VBD	_	_	0	ROOT	_	_
6	as	_	IN	_	_	5	VMOD	_	_
7	a	_	DT	_	_	9	NMOD	_	_
8	broad	_	JJ	_	_	9	NMOD	_	_
9	band	_	NN	_	_	6	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	50-60	_	CD	_	_	12	NMOD	_	_
12	kDa	_	NN	_	_	10	PMOD	_	_
13	,	_	,	_	_	5	P	_	_
14	whereas	_	IN	_	_	5	VMOD	_	_
15	with	_	IN	_	_	23	VMOD	_	_
16	U937	_	NN	_	_	19	NMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	HL60	_	NN	_	_	17	CONJ	_	_
19	cells	_	NNS	_	_	15	PMOD	_	_
20	a	_	DT	_	_	22	NMOD	_	_
21	diffuse	_	JJ	_	_	22	NMOD	_	_
22	band	_	NN	_	_	23	VMOD	_	_
23	was	_	VBD	_	_	14	SUB	_	_
24	observed	_	VBN	_	_	23	VC	_	_
25	at	_	IN	_	_	24	VMOD	_	_
26	approximately	_	RB	_	_	28	NMOD	_	_
27	55	_	CD	_	_	26	DEP	_	_
28	kDa	_	NN	_	_	25	PMOD	_	_
29	.	_	.	_	_	5	P	_	_
		
1	Treatment	_	NN	_	_	11	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	K562	_	NN	_	_	4	NMOD	_	_
4	cells	_	NNS	_	_	2	PMOD	_	_
5	with	_	IN	_	_	1	NMOD	_	_
6	tunicamycin	_	NN	_	_	5	PMOD	_	_
7	for	_	IN	_	_	6	NMOD	_	_
8	18	_	CD	_	_	9	NMOD	_	_
9	h	_	NN	_	_	7	PMOD	_	_
10	,	_	,	_	_	1	P	_	_
11	resulted	_	VBD	_	_	0	ROOT	_	_
12	in	_	IN	_	_	11	VMOD	_	_
13	extensive	_	JJ	_	_	14	NMOD	_	_
14	loss	_	NN	_	_	12	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	the	_	DT	_	_	19	NMOD	_	_
17	50-60	_	CD	_	_	18	AMOD	_	_
18	kDa	_	NN	_	_	19	NMOD	_	_
19	glycoprotein	_	NN	_	_	15	PMOD	_	_
20	,	_	,	_	_	14	P	_	_
21	appearance	_	NN	_	_	14	COORD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	a	_	DT	_	_	26	NMOD	_	_
24	30-40	_	CD	_	_	25	AMOD	_	_
25	kDa	_	NN	_	_	26	NMOD	_	_
26	band	_	NN	_	_	22	PMOD	_	_
27	and	_	CC	_	_	21	COORD	_	_
28	increased	_	VBN	_	_	29	NMOD	_	_
29	staining	_	NN	_	_	27	CONJ	_	_
30	of	_	IN	_	_	29	NMOD	_	_
31	a	_	DT	_	_	34	NMOD	_	_
32	45	_	CD	_	_	33	AMOD	_	_
33	kDa	_	NN	_	_	34	NMOD	_	_
34	band	_	NN	_	_	30	PMOD	_	_
35	.	_	.	_	_	11	P	_	_
		
1	With	_	IN	_	_	7	VMOD	_	_
2	U937	_	NN	_	_	3	NMOD	_	_
3	cells	_	NNS	_	_	1	PMOD	_	_
4	,	_	,	_	_	7	P	_	_
5	tunicamycin	_	NN	_	_	6	NMOD	_	_
6	treatment	_	NN	_	_	7	VMOD	_	_
7	resulted	_	VBD	_	_	0	ROOT	_	_
8	in	_	IN	_	_	7	VMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	appearance	_	NN	_	_	8	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	a	_	DT	_	_	15	NMOD	_	_
13	30-40	_	CD	_	_	14	AMOD	_	_
14	kDa	_	NN	_	_	15	NMOD	_	_
15	band	_	NN	_	_	11	PMOD	_	_
16	and	_	CC	_	_	10	COORD	_	_
17	increased	_	VBN	_	_	18	NMOD	_	_
18	staining	_	NN	_	_	16	CONJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	a	_	DT	_	_	23	NMOD	_	_
21	45	_	CD	_	_	22	AMOD	_	_
22	kDa	_	NN	_	_	23	NMOD	_	_
23	band	_	NN	_	_	19	PMOD	_	_
24	.	_	.	_	_	7	P	_	_
		
1	With	_	IN	_	_	11	VMOD	_	_
2	HL60	_	NN	_	_	3	NMOD	_	_
3	cells	_	NNS	_	_	1	PMOD	_	_
4	loss	_	NN	_	_	11	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	10	NMOD	_	_
7	55	_	CD	_	_	8	AMOD	_	_
8	kDa	_	NN	_	_	10	NMOD	_	_
9	Glut-1	_	NN	_	_	10	NMOD	_	_
10	band	_	NN	_	_	5	PMOD	_	_
11	was	_	VBD	_	_	0	ROOT	_	_
12	observed	_	VBN	_	_	11	VC	_	_
13	and	_	CC	_	_	11	COORD	_	_
14	a	_	DT	_	_	15	NMOD	_	_
15	band	_	NN	_	_	19	VMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	45	_	CD	_	_	18	NMOD	_	_
18	kDa	_	NN	_	_	16	PMOD	_	_
19	appeared	_	VBD	_	_	13	CONJ	_	_
20	.	_	.	_	_	11	P	_	_
		
1	Tunicamycin-treatment	_	NN	_	_	2	VMOD	_	_
2	resulted	_	VBD	_	_	0	ROOT	_	_
3	in	_	IN	_	_	2	VMOD	_	_
4	75-90	_	CD	_	_	5	AMOD	_	_
5	%	_	NN	_	_	6	NMOD	_	_
6	inhibition	_	NN	_	_	3	PMOD	_	_
7	in	_	IN	_	_	6	NMOD	_	_
8	[3H]mannose	_	NN	_	_	9	NMOD	_	_
9	incorporation	_	NN	_	_	7	PMOD	_	_
10	but	_	CC	_	_	6	COORD	_	_
11	only	_	RB	_	_	10	COORD	_	_
12	20-25	_	CD	_	_	13	AMOD	_	_
13	%	_	NN	_	_	14	NMOD	_	_
14	inhibition	_	NN	_	_	10	CONJ	_	_
15	in	_	IN	_	_	14	NMOD	_	_
16	[3H]thymidine	_	NN	_	_	19	NMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	[3H]leucine	_	NN	_	_	17	CONJ	_	_
19	incorporation	_	NN	_	_	15	PMOD	_	_
20	.	_	.	_	_	2	P	_	_
		
1	In	_	IN	_	_	5	VMOD	_	_
2	contrast	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	tunicamycin	_	NN	_	_	5	VMOD	_	_
5	had	_	VBD	_	_	0	ROOT	_	_
6	little	_	JJ	_	_	7	NMOD	_	_
7	effect	_	NN	_	_	5	VMOD	_	_
8	on	_	IN	_	_	5	VMOD	_	_
9	the	_	DT	_	_	13	NMOD	_	_
10	viability	_	NN	_	_	13	NMOD	_	_
11	and	_	CC	_	_	10	COORD	_	_
12	MTT	_	NN	_	_	11	CONJ	_	_
13	responses	_	NNS	_	_	8	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	cells	_	NNS	_	_	14	PMOD	_	_
17	used	_	VBN	_	_	16	APPO	_	_
18	.	_	.	_	_	5	P	_	_
		
1	These	_	DT	_	_	2	NMOD	_	_
2	results	_	NNS	_	_	3	VMOD	_	_
3	suggest	_	VBP	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	VMOD	_	_
5	in	_	IN	_	_	11	VMOD	_	_
6	leukemic	_	JJ	_	_	7	NMOD	_	_
7	cells	_	NNS	_	_	5	PMOD	_	_
8	N-glycosylation	_	NN	_	_	11	VMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	Glut-1	_	NN	_	_	9	PMOD	_	_
11	plays	_	VBZ	_	_	4	SUB	_	_
12	an	_	DT	_	_	14	NMOD	_	_
13	important	_	JJ	_	_	14	NMOD	_	_
14	role	_	NN	_	_	11	VMOD	_	_
15	in	_	IN	_	_	11	VMOD	_	_
16	maintaining	_	VBG	_	_	15	PMOD	_	_
17	its	_	PRP$	_	_	18	NMOD	_	_
18	structure	_	NN	_	_	16	VMOD	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	functional	_	JJ	_	_	21	NMOD	_	_
21	integration	_	NN	_	_	19	CONJ	_	_
22	.	_	.	_	_	3	P	_	_
		
